(Q30354538)

English

Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: a Phase 1 dose-escalation study in healthy adults.

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: a Phase 1 dose-escalation study in healthy adults. (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

influenza vaccine

1 reference

based on heuristic

inferred from title

object named as

James E Moon

3

0 references

Jacqueline M. Katz

9

object named as

Jacqueline M Katz

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

10

object named as

Vidadi Yusibov

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

author name string

James F Cummings

1

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

Melanie L Guerrero

2

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

Paige Waterman

4

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

Robin K Nielsen

5

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

Stacie Jefferson

6

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

F Liaini Gross

7

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

Kathy Hancock

8

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

Fraunhofer USA Center for Molecular Biotechnology Study Group

11

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

language of work or name

0 references

publication date

12 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

2251-2259

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Emergence of a novel swine-origin influenza A (H1N1) virus in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Influenza vaccines: the good, the bad, and the eggs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Response to a monovalent 2009 influenza A (H1N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

A Single Dose of Unadjuvanted Novel 2009 H1N1 Vaccine Is Immunogenic and Well Tolerated in Young and Elderly Adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Recent progress in the development of plant derived vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Plants as bioreactors: Recent developments and emerging opportunities

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Plant-made vaccines for humans and animals.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Immunogenicity of a subunit vaccine against Bacillus anthracis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

A plant-produced plague vaccine candidate confers protection to monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Plant-expressed HA as a seasonal influenza vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

A plant-based system for rapid production of influenza vaccine antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

A launch vector for the production of vaccine antigens in plants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

A rapid immune response to 2009 influenza A(H1N1) vaccines in adults: a randomized, double-blind, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

A novel influenza A (H1N1) vaccine in various age groups.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.017

7 January 2021

Identifiers

10.1016/J.VACCINE.2013.10.017

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30354538&oldid=1642764210"